Form 8-K - Current report:
SEC Accession No. 0001193125-25-200205
Filing Date
2025-09-10
Accepted
2025-09-10 17:22:34
Documents
15
Period of Report
2025-09-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d907117d8k.htm   iXBRL 8-K 33879
2 EX-1.1 d907117dex11.htm EX-1.1 219572
3 EX-5.1 d907117dex51.htm EX-5.1 8474
7 GRAPHIC g907117g0910234832207.jpg GRAPHIC 2654
  Complete submission text file 0001193125-25-200205.txt   446511

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rapp-20250909.xsd EX-101.SCH 2854
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rapp-20250909_lab.xml EX-101.LAB 18735
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rapp-20250909_pre.xml EX-101.PRE 11709
17 EXTRACTED XBRL INSTANCE DOCUMENT d907117d8k_htm.xml XML 3765
Mailing Address 99 HIGH STREET SUITE 2100 BOSTON MA 02110
Business Address 99 HIGH STREET SUITE 2100 BOSTON MA 02110 857-321-8020
Rapport Therapeutics, Inc. (Filer) CIK: 0002012593 (see all company filings)

EIN.: 880724208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42121 | Film No.: 251306643
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)